Free Priority Shipping on USA orders over $150 – 24‑hr processing – Live phone support
Free Priority Shipping on USA orders over $150 – 24‑hr processing – Live phone support
$500.00
Retratrutide (LY3437943) is an investigational peptide engineered as a triple agonist at the GIP, GLP‑1, and glucagon receptors, making it a high‑interest molecule in metabolic and obesity research. Current preclinical and clinical studies evaluate its role in energy balance, glucose homeostasis, and body‑weight regulation, positioning it as a next‑generation research tool rather than an approved therapeutic.
All Retratrutide offered by Peak Science Peptides is pharmaceutical‑grade, manufactured under stringent quality standards, and accompanied by independent third‑party laboratory analysis to verify identity, purity, and potency for research applications. This product is supplied strictly for in vitro and in vivo research in controlled laboratory environments and is not intended for human consumption, medical use, or any non‑research purpose.
Retratrutide is a synthetic 39‑amino‑acid peptide that simultaneously activates glucose‑dependent insulinotropic polypeptide (GIP), glucagon‑like peptide‑1 (GLP‑1), and glucagon receptors. This multi‑receptor profile differentiates it from single or dual incretin agonists and has made it a focal point of metabolic disease research programs worldwide.
In published phase 2 studies, this triple agonist mechanism has been associated with substantial reductions in body weight and improvements in markers of insulin sensitivity and lipid metabolism, under controlled clinical conditions. Regulatory agencies continue to evaluate safety and efficacy data, and Retratrutide remains an investigational agent, not an approved drug product.
In research settings, Retratrutide is used to probe how simultaneous activation of GIP, GLP‑1, and glucagon receptors influences energy intake, energy expenditure, and metabolic signaling cascades. At a mechanistic level, receptor activation increases intracellular cyclic AMP (cAMP) and downstream pathways that modulate insulin secretion, hepatic glucose output, lipid metabolism, and appetite‑related signaling in preclinical models.
Triple agonism allows investigators to study how glucagon‑driven energy expenditure interacts with incretin‑mediated appetite and glucose control, an area of growing interest as obesity pharmacotherapy shifts from single‑pathway to multi‑pathway approaches. Experimental data from phase 2 trials have reported mean body‑weight reductions exceeding 20% over 48 weeks at higher doses, highlighting the relevance of this peptide for obesity and metabolic dysfunction research designs.
Unlike single GLP‑1 agonists or dual GIP/GLP‑1 agonists, Retratrutide also targets the glucagon receptor, enabling concurrent modulation of appetite, insulin signaling, and energy expenditure in experimental models. Comparative analyses suggest that this triple‑action profile can produce greater weight‑loss and metabolic effects at given exposure levels, although long‑term safety and optimal use parameters remain under active investigation.
In a 48‑week phase 2 obesity trial, higher‑dose Retratrutide regimens produced mean body‑weight reductions around 22–24%, compared with approximately 2% for placebo under controlled conditions. These studies also reported improvements in insulin sensitivity, liver fat reduction, and favorable changes in visceral adipose tissue, while monitoring gastrointestinal and other adverse events typical of incretin‑based therapies.
Because Retratrutide is a peptide research material, laboratories typically follow standard peptide handling procedures, including controlled storage conditions, appropriate protective equipment, and validated documentation of batch numbers and certificates of analysis. Peak Science Peptides supplies third‑party lab test results with each lot so that research teams can confirm purity and identity before integrating the compound into experimental protocols.
Reviews
There are no reviews yet.